Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

Sampei, Zenjiro; Igawa, Tomoyuki; Soeda, Tetsuhiro; Okuyama-Nishida, Yukiko; Moriyama, Chifumi; Wakabayashi, Tetsuya; Tanaka, Eriko; Muto, Atsushi; Kojima, Tetsuo; Kitazawa, Takehisa; Yoshihashi, Kazutaka; Harada, Aya; Funaki, Miho; Haraya, Kenta; Tachibana, Tatsuhiko; Suzuki, Sachiyo; Esaki, Keiko; Nabuchi, Yoshiaki; Hattori, Kunihiro
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors). To overcome these drawbacks, we screened asymmetric bispecific IgG antibodies to factor IXa (FIXa) and factor X (FX), mimicking the FVIII cofactor function. Since the therapeutic potential of the lead bispecific antibody was marginal, FVIII-mimetic activity was improved by modifying its binding properties to FIXa and FX, and the pharmacokinetics was improved by engineering the charge properties of the variable region. Difficulties in manufacturing the bispecific antibody were overcome by identifying a common light chain for the anti-FIXa and anti-FX heavy chains through framework/complementarity determining region shuffling, and by pI engineering of the two heavy chains to facilitate ion exchange chromatographic purification of the bispecific antibody from the mixture of byproducts. Engineering to overcome low solubility and deamidation was also performed. The multidimensionally optimized bispecific antibody hBS910 exhibited potent FVIII-mimetic activity in human FVIII-deficient plasma, and had a half-life of 3 weeks and high subcutaneous bioavailability in cynomolgus monkeys. Importantly, the activity of hBS910 was not affected by FVIII inhibitors, while anti-hBS910 antibodies did not inhibit FVIII activity, allowing the use of hBS910 without considering the development or presence of FVIII inhibitors. Furthermore, hBS910 could be purified on a large manufacturing scale and formulated into a subcutaneously injectable liquid formulation for clinical use. These features of hBS910 enable routine prophylaxis by subcutaneous delivery at a long dosing interval without considering the development or presence of FVIII inhibitors. We expect that hBS910 (investigational drug name: ACE910) will provide significant benefit for severe hemophilia A patients.


Related Articles

  • The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A. Lacroix-Desmazes, Sébastien; Bayry, Jagadeesh; Misra, Namita; Horn, Michael P.; Villard, Sylvie; Pashov, Anastas; Stieltjes, Natalie; d'Oiron, Roseline; Saint-Remy, Jean-Marie; Hoebeke, Johan; Kazatchkine, Michel D.; Reinbolt, Joseph; Mohanty, Dipika; Kaveri, Srini V. // New England Journal of Medicine;2/28/2002, Vol. 346 Issue 9, p662 

    Background: Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti–factor VIII antibodies has been proposed as a mechanism of inactivation of factor VIII. Methods:...

  • SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†. Davis, Jonathan H.; Aperlo, Christel; Yue Li; Kurosawa, Emmi; Yan Lan; Kin-Ming Lo; Huston, James S. // PEDS: Protein Engineering, Design & Selection;Apr2010, Vol. 23 Issue 4, p195 

    Bispecific antibodies and asymmetric Fc fusion proteins offer opportunities for important advances in therapeutics. Bivalent IgG depends upon in vivo dimerization of its heavy chains, mediated by homodimeric association of its CH3 domains. We have developed a heterodimeric Fc platform that...

  • Researchers Show Bispecific Antibodies Move to Hemophilia.  // BioWorld Today;10/ 8/2012, Vol. 23 Issue 195, Special section p1 

    The article focuses on a bispecific antibody created by researchers from Chugai Pharmaceuticals Inc. that could mimic the effect of Factor VIII, a protein in the blood-clotting cascade that is missing in hemophilia A.

  • Recombinant approaches to IgG-like bispecific antibodies. Marvin, Jonathan S.; Zhenping Zhu // Acta Pharmacologica Sinica;Jun2005, Vol. 26 Issue 6, p649 

    One of the major obstacles in the development of bispecific antibodies (BsAb) has been the difficulty of producing the materials in sufficient quality and quantity by traditional technologies, such as the hybrid hybridoma and chemical conjugation methods. In contrast to the rapid and significant...

  • A modular IgG-scFv bispecific antibody topology. Orcutt, Kelly Davis; Ackerman, Margaret E.; Cieslewicz, Maryelise; Quiroz, Emmanuel; Slusarczyk, Adrian L.; Frangioni, John V.; Wittrup, K. Dane // PEDS: Protein Engineering, Design & Selection;Apr2010, Vol. 23 Issue 4, p221 

    Here we present a bispecific antibody (bsAb) format in which a disulfide-stabilized scFv is fused to the C-terminus of the light chain of an IgG to create an IgG-scFv bifunctional antibody. When expressed in mammalian cells and purified by one-step protein A chromatography, the bsAb retains...

  • 2012 BJA/PGA Supplement.  // BJA: The British Journal of Anaesthesia;Dec2012 Supplement 1, Vol. 109, pNP 

    No abstract available.

  • QUESTION & ANSWER.  // JAAPA: Journal of the American Academy of Physician Assistants (;Apr2013, Vol. 26 Issue 4, p46 

    A quiz related to Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) is presented.

  • Animal models: Dogged pursuit. Sohn, Emily // Nature;11/27/2014 Supplement, Vol. 515 Issue s7528, pS172 

    The article offers information on the treatment of hemophilia, a rare bleeding disorder in dogs. A brief history of the use of dogs to find a line of treatment through the years is mentioned. It discusses techniques including gene therapy to cure this disorder, and studies conducted on dogs to...

  • Bioengineered protein shows preliminary promise as new therapy for hemophilia.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p249 

    The article reports on the result of a study which engineers the coagulation factor Xa (FXa), a protein active in blood clotting, into a variant which could control bleeding in mouse models with hemophilia. According to researcher Rodney A. Camire, the form of the variant FXa changes when it...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics